ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation $(GKOS)$, a leading ophthalmic pharmaceutical and medical technology company, has announced receiving European Union Medical Device Regulation $(MDR.AU)$ certification for its iStent infinite® and other micro-invasive glaucoma surgery (MIGS) technologies, including iStent inject® W. This marks the company's first regulatory clearances under the new EU regulatory framework. These certifications highlight that the devices meet the stringent quality, safety, and effectiveness standards set by the EU MDR. The approval supports Glaukos' efforts to expand its presence in Europe and propel its global Interventional Glaucoma initiatives. Glaukos, the global market leader in MIGS, plans to commence commercial launch activities for these therapies in the coming months.